Administration
PATIENT GROUP DIRECTION (PGD) FOR

PROXYMETACAINE 0.5% EYE DROPS

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition	
Indication	To be used as a topical ocular local anaesthetic
Inclusion criteria	Patients presenting in MIU with conditions requiring examination, removal of foreign bodies or irrigation of the eye
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Known hypersensitivity to any of the ingredients of the drops Premature babies Traumatised eye and penetrating injuries Red (inflamed) eye without history of trauma
Cautions - Seek further advice from doctor before proceeding and document advice	Not to be used with contact lenses in situ When using with fluorescein, instil after the eye has been anaesthetised. Safety for use in pregnancy and lactation has not been established, therefore, use only when considered essential This product should be used cautiously and sparingly in patients with known allergies, cardiac disease or hyperthyroidism because of the increased risk of sensitivity reactions.
Further information	The drops may be washed away with sterile isotonic sodium chloride 0.9% solution (normal saline) A period of one minute must be left before administration of any other eye drops Do not use if the solution is more than pale yellow in colour. Discard after single use. Store unrefridgerated at below 25°C
Action if patient declines or is excluded	Refer to doctor / A&E / ophthalmologist as appropriate and document
Drug Details	
Name, form & strength of medicine	Proxymetacaine hydrochloride 0.5% single use sterile eye drops (minims)
Legal status	Prescription Only Medicine (POM)
Route/Method	Into the affected eye or eyes Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following instillation of the drops. (This blocks the passage of the drops via the naso lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially useful in children).
Dosage	Instil one or two drops
Frequency	Once only
Quantity to administer	See above

Administration
PATIENT GROUP DIRECTION (PGD) FOR

PROXYMETACAINE 0.5% EYE DROPS

Side effects	May cause transient blurring of vision on instillation
Advice to patient/carer	Protection of the eye from rubbing, irritating chemicals and foreign bodies during the period of anaesthesia is very important. Patients should be advised to avoid touching the eye until the anaesthesia has worn off. Warn patients not to drive or operate hazardous machinery unless vision is clear (blurring of vision on instillation). Anaesthesia lasts for approximately 30 minutes. Do not wear contact lenses for 24 hours after the anaesthesia
Follow up	Patient should be followed up by GP at 24 to 48 hours

Staff Characteristics	
Professional qualifications	Nurses on the NMC Register
Specialist competencies or qualifications	A registered nurse, after discussion and agreement with the MIU service/departmental lead. Has undertaken training to carry out clinical assessment of minor injuries to eyes leading to diagnosis that requires treatment according to the indications listed in this PGD Has undertaken appropriate training for working under PGDs for the supply and administration of medicines Has undertaken training in the management of anaphylaxis
Continuing education & training	The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development
Referral Arrangements and Audit Trail	
Records/audit trail	Patient's name, address, date of birth. Contact details of GP (if registered). Diagnosis. Advice given to patient (including side effects). Signature/name of staff who administered the medication. Details of any adverse drug reaction and actions taken including documentation in the patient's medical record Referral arrangements (including self-care) Record the use of the PGD in the departmental log.
References/Resources and comments	Summary of Product Characteristics British National Formulary

Administration
PATIENT GROUP DIRECTION (PGD) FOR

PROXYMETACAINE 0.5% EYE DROPS

Clinical Authorisation		
Lead Doctor	Dr John Devapriam, Medical Director Signature: [signature] Date: 14/6/18	
Lead Pharmacist	Dr Alex Johnson, Prescribing Support Pharmacist Signature: [signature] Date: 26.6.18	
Organisational Authorisation		
On behalf of Worcestershire Health and Care NHS Trust	Michelle Clarke, Director of Nursing and Quality Signature: [signature] Date: 18/6/18	
Patient Group Direction Peer Reviewed by		
Senior MIU Nurses		

Administration
PATIENT GROUP DIRECTION (PGD) FOR

PROXYMETACAINE 0.5% EYE DROPS

Individual Authorisation

PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY.

It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct.

Note to Authorising Managers: authorised staff should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation. Authorising managers should be sure that staff signed up to use the PGD have the necessary competence, training and knowledge to apply it.

I have read and understood the Patient Group Direction and agree to supply/administer this medicine only in accordance with this PGD. I confirm that I have the necessary competence, training and knowledge to apply it.

Name of Professional	Signature	Authorising Manager	Date